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Abstract 
A double-blinded, placebo controlled, cross-over design was used to investigate sodium 
citrate dihydrate (Na-CIT) supplementation improve 200m swimming performance. Ten 
well-trained, male swimmers (14.9 ± 0.4y; 63.5 ± 4kg) performed four 200m time trials: 
acute (ACU) supplementation (0.5g/kg), acute placebo (PLC-A), chronic (CHR) (0.1g/kg 
for 3 days and 0.3g/kg on the 4
th
 day pre-trial), and chronic placebo (PLC-C).  Na-CIT 
was administered 120min pre-trial in solution with 500mL of flavored water; placebo was 
flavored water. Blood lactate, base excess (BE), bicarbonate, pH, and PCO2 were 
analyzed at basal, 100min post-ingestion, and 3min post-trial via finger prick. Time, 
lactate, and rate of perceived exertion were not different between trials. BE and 
bicarbonate were significantly higher for the ACU and CHR trials compared to placebo. 
“Responders” improved by 1.03% (P=0.043) and attained significantly higher post-trial 
lactate concentrations in the ACU versus PLC-A trials and compared to non-responders 
in the ACU and CHR trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Table of Contents 
 
Abstract          ii 
Table of Contents         iii 
List of Tables          iv 
List if Figures          iv 
List of Appendices         iv 
List of Abbreviations         v 
 
Chapter 1: Introduction 
1.1 Rational         6 
1.2 Objectives and Hypotheses      8 
  1.2.1 Research Objectives      8 
  1.2.2 Research Hypotheses      9 
 
Chapter 2: Literature Review 
 2.1 Bioenergetics of High-Intensity Exercise     10 
 2.2 Anaerobic Metabolism       11 
2.3 Fatigue         12 
 2.4 Enhancement of Performance in Sport     13 
2.5 Alkalizing Agents        14 
 2.5.1 Sodium Citrate       16 
2.6 Sodium Citrate Supplementation in Athletes    17 
 2.6.1 Finding the optimal Protocol     18 
 2.6.2 Sodium Bicarbonate versus Sodium Citrate   19 
  2.6.3 Acute Effects during High-Intensity Sport Specific Exercise 20 
  2.6.4 Intermittent Exercise      24 
  2.6.5 Effects on Cardio-Respiratory Performance   24 
  2.6.6 Effects on Recovery      26 
2.7 Swimming         27 
2.8 Side Effects of Sodium Citrate Ingestion     28 
2.9 Conclusion        29 
 
Chapter 3: Methods 
 3.1 Participants        37 
 3.2 Experimental Design       37 
 3.3 Sodium Citrate Dihydrate and Placebo Loading Protocol  38 
3.4 200m Swim Trials        39 
3.5 Blood Sampling and Analysis      39 
3.6 Statistical Analysis        40 
 
Chapter 4: Results 
 4.1 200m Swim Trials        42 
 4.2 Lactate Concentrations       45 
iv 
 
 4.3 Physiological Response to Na-CIT      47 
 
Chapter 5: Discussion and Conclusion 
 5.1 Discussion         51 
 5.2 Conclusion        56 
 5.3 Study limitations and Future Directions     57 
 5.4 Future Research        58 
 
References          60 
 
Appendices          69 
 
List of Tables  
 
Table 1 Complete Literature Review of Citrate (Feb. 2013)    30 
Table 2 Anthropometrics        45 
 
List of Figures 
 
Figure 1 200m Performance Times       43 
Figure 2 Ratings of Perceived Exertion      43 
Figure 3 Individual Performance (PLC-A versus ACU)    44 
Figure 4 Lactate         46 
Figure 5 Responders versus Non-Responders Lactate    46 
Figure 6 Base Excess         47 
Figure 7 Bicarbonate         49 
Figure 8 pH          49 
Figure 9 PCO2          50 
 
List of Appendices 
 
Appendix 1 Ratings of Perceived Exertion      70 
Appendix 2 Brock Research Ethics Board Letter of Approval    71 
Appendix 3 Health Canada Letter of Approval     72 
Appendix 4 Letter of Invitation       73 
Appendix 5 Parent / Guardian Informed Consent     75 
Appendix 6 Participant Informed Assent      79 
Appendix 7 Raw Data         83 
 
 
 
 
 
v 
 
 List of Abbreviations 
 
ACU  Acute 
ALD  Aldosterone 
ANOVA Analysis of variance 
ATP  Adenosine triphosphate 
BE  Base excess 
CHR  Chronic 
CIT  Citrate anion 
Cl-  Chloride ion 
DA  Dopamine 
EPI  Epinephrine 
GI  Gastrointestinal 
H  Hypoxia 
H+  Hydrogen ion 
HH  Hypobaric hypoxia 
h-CHO  High carbohydrate 
K+  Potassium ion 
MVC  Maximal voluntary contraction 
Na+  Sodium ion 
NaCl  Sodium chloride 
Na-CIT  Sodium citrate 
NaHCO3 Sodium bicarbonate 
NaLac  Sodium lactate 
NE  Norepinephrine 
NH4Cl  Ammonium chloride 
No  Normoxia 
PaCO2  Arterial partial pressure of carbon dioxide 
PaO2  Arterial partial pressure of oxygen 
PCO2  Venous partial pressure of carbon dioxide 
PFK  Phosphofructokinase 
PLC  Placebo 
PLC-A  Acute placebo 
PLC-C  Chronic placebo 
RER  Respiratory exchange ratio 
RPE  Rate of perceived exertion 
VE  Ventilation rate 
 
 
6 
 
Chapter 1: Introduction 
 
1.1 Rational 
 
Anaerobic glycolysis quickly provides adenosine triphosphate (ATP) for muscle 
contraction during high intensity, short duration exercise. The fast rate of glycolysis 
during anaerobic exercise results in pyruvate formation exceeding pyruvate oxidation 
and results in a buildup of lactic acid (Wells et al. 2009, Street et al. 2005). Lactic acid 
dissociates quickly to lactate and hydrogen ions (H+), which causes a decrease in muscle 
and blood pH (Wells et al. 2009). The increase in H+ causes impaired release of calcium 
from the sarcoplasmic reticulum and calcium ion binding that inhibits the coupling of 
actin and myosin (Katz et al. 1984, Requena et al. 2005). This intracellular acidosis is 
directly related to fatigue that is defined as a decrease in force production with an 
increased perception of effort (Enoka & Stuart 1992). 
Ingestion of sodium citrate (Na-CIT), an alkalizing agent, increases extracellular 
pH as it is metabolized to bicarbonate. Studies have confirmed (Katz et al. 1984, 
McNaughton 1990, McNaughton & Cedaro 1992, Oopik et al. 2003, Robergs et al. 2005) 
that increasing extracellular pH facilitates the efflux of Lactate and H+ from active 
muscles compared to placebo. Therefore, artificially inducing alkalosis prior to anaerobic 
exercise may reduce intracellular acidosis and increase the time to fatigue. 
Researchers have studied sodium bicarbonate (Katz et al. 1984, McNaughton et 
al. 2008) and Na-CIT (Jain et al. 2003, Kowalchuk et al. 1989, Linossier et al. 1997, 
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McNaughton 1990) as potential alkalizing agents. A meta-analysis by Carr et al. (2011) 
reported that ingestion of sodium bicarbonate at a dose of 0.3g/kg, 90min pre-trial 
enhances anaerobic performance, but the ingestion of Na-CIT did not appear to alter 
anaerobic performance. Indeed, Na-CIT has been studied over a broad array of does, 
times, and events with inconclusive results (Linossier et al. 1997, McNaughton 1990, 
McNaughton & Cedaro 1992, Oopik et al. 2003, Oopik et al. 2004, Potteiger et al. 1996, 
Zochowski et al. 2009).  
McNaughton et al. (1990, 1992) investigated the Na-CIT for the optimal dose and 
performance duration to elicit a potential ergogenic effect. They concluded that 0.5g/kg 
of body mass, 90 - 120min prior to maximal effort represented the optimal conditions 
for a potential ergogenic effect in events lasting 60 - 240s. In the case where Na-CIT was 
given at a dose of 0.6g/kg, 5 of the 8 participants developed gastrointestinal (GI) 
discomfort which negatively impacted performance (Schabort et al. 2000). None-the-
less, Na-Cit exhibited an improved GI acceptance profile over the more commonly used 
sodium bicarbonate (Requena et al. 2005). 
Na-Cit is not banned by the world anti-doping agency (WADA 2013 Prohibited List); 
however, it is not as popular as a supplement compared to sodium bicarbonate due to 
the inconsistent performance effects found in the literature. On the other hand, Na-Cit 
has been suggested to have less GI discomfort than sodium bicarbonate and, therefore, 
may be a superior alternative. A randomized, cross-over, placebo controlled trial, as is 
proposed in this study, would be the best method to prove the potential benefit of Na-
Cit on swimming performance in an anaerobic event. Furthermore, testing a novel 
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chronic dosing regimen may eliminate any GI symptoms that hinder performance when 
ingesting alkalizing agents at high, acute doses. Lastly, this will also be the first study 
that looks at the highly competitive adolescent population in swimming. The 
competitive nature of sport has presented an atmosphere where 80% of high level 
adolescent athletes are using supplements and other non-doping strategies to improve 
performance without any research into the effectiveness of such ergogenic aids in the 
young population (Braun et al. 2009). 
 
1.2 Objectives and Hypotheses 
 
1.2.1 Research Objectives 
 
The main objective of this study was to evaluate the impact of multiple dosing regimens 
of sodium citrate ingestion on exercise performance, hematological variables, and 
parameters of aerobic and anaerobic physiology in well-trained adolescent male 
swimmers. Specifically, a double-blinded, placebo controlled, cross-over design was 
used to investigate whether Na-CIT ingestion improves 200m swimming performance in 
male adolescent swimmers. Differences between acute versus chronic Na-CIT 
supplementation will also be examined. 
The primary outcome variable was performance time (s) and the secondary 
variables was lactate concentration (mmol/L), rate of perceived exertion (RPE), venous 
9 
 
partial pressure (PCO2) (mmHg), base excess (mmol/L), and bicarbonate concentration 
(mmol/L). 
 
1.2.2 Research Hypotheses 
 
The null hypotheses that were evaluated were: i) sodium citrate ingestion (chronic and 
acute) will not have an effect on exercise performance compared to placebo; and ii) 
there will be no difference between chronic and acute treatments on the 200m 
performance times. 
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Chapter 2: Review of Literature 
 
2.1 Bioenergetics of High-Intensity Exercise 
 
Three energy systems are utilized for ATP turnover and resynthesis in the human body: 
1) the alacti anaerobic system, 2) the lactic anaerobic system, and 3) the aerobic 
oxidative system. At the onset of exercise all energy systems contribute to energy 
production but their relative contribution varies as a function of the duration and 
intensity of the exercise (Wilmore & Costill 2004). The alactic anaerobic system derives 
its energy from the breakdown of creatine phosphate and is the primary source of 
energy provision for 12-15 seconds. The lactic anaerobic system takes over as the 
principal energy supplier through the breakdown of muscle glycogen to lactate for the 
production of ATP (anaerobic glycolysis). The body relies on anaerobic glycolysis as the 
primary energy system for high-intensity, short duration exercise lasting greater than 12 
– 15 seconds and less than 2min (Wilmore & Costill 2004). Quantification of anaerobic 
energy release and, hence, its percent contribution to energy production for a given 
amount of time can be analyzed directly by measuring lactate production and 
phosphocreatine breakdown or indirectly by accumulated oxygen deficit (Medbo & 
Tabata 1989).  When exactly during high-intensity exercise the anaerobic energy 
provision reaches 50% with aerobic oxidative metabolism contributing the other 50% is 
a source of contention and may stem from how anaerobic energy release is quantified 
and the muscle mass engaged in a given exercise (Medbo & Tabata 1989, Spriet et al. 
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1987). None-the-less, at 60 - 120s the aerobic oxidative system takes over as the 
primary source of energy provision. This is accomplished by the breakdown on muscle 
glycogen, in the presence of oxygen, for a more efficient production of ATP. The 
pyruvate derived from the breakdown of glucose then converted to Acetyl-CoA as a 
substrate for the Krebs cycle. Furthermore, the breakdown of free fatty acids plays an 
important role in the aerobic energy production (Wilmore & Costill 2004). 
 
2.2 Anaerobic Metabolism 
 
Energy production via anaerobic glycolysis takes place in the cytoplasm of each skeletal 
muscle cell by catabolism of glucose or muscle glycogen to pyruvate through 10 enzyme 
driven steps (Spriet et al. 2000). The ATP derived from glycolysis is rendered at a high 
rate for rapid and powerful muscular contraction; however, with such high rates of 
glycolytic flux, pyruvate formation exceeds pyruvate oxidation. Oxidized pyruvate is 
converted to lactic acid to maintain the rate of anaerobic glycolysis and energy 
production (Wells et al. 2009). Athletes performing sporting events, such as swimming, 
downhill skiing, 800m run, 1500m speed skating, and most team sports, rely on 
anaerobic metabolism as the primary driver for energy provision. 
Lactic acid dissociates quickly to lactate and H+ which causes a decrease in 
muscle and blood pH (Costill et al. 1984). In order to maintain exercise at high intensity, 
removal of lactic acid from Type II glycolytic muscle fibres, where lactate is 
predominantly produced, to Type I oxidative fibres, where lactic acid can be oxidized in 
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mitochondria, must be efficient. The transfer of lactate and H+ is accomplished via pH 
sensitive monocarboxylate lactate transporters located on the surface of the 
sarcolemma (Wells et al. 2009).  
The lactate that quickly accumulates during high intensity exercise is a commonly 
measured variable in sport physiology. Typical values range from 1 - 2mmol/L at rest, to 
4mmol/L in moderate sustainable exercise, to greater than 16mmol/L in maximal 
anaerobic exercise. There is a close relationship between blood lactate concentration 
and fatigue during high intensity exercise. However, this does not account for fatigue 
and cramps observed during high-intensity exercise in individuals with 
glycolytic/glycogenolytic disorders, in which glycolysis, and therefore lactate production, 
is blocked (Wells et al. 2009). Hence, many other variables may contribute to fatigue 
found in muscle cells. Indeed, the decrease in muscle and blood pH that corresponds 
with an increase in lactate is a major factor that produces fatigue (Noakes 2000). It is 
due to these factors, as well as the relative ease with which blood lactate can be 
measured, that lactic acid and lactate have been of considerable interest to exercise 
scientists for many years (Juel 1997, Stallknecht et al. 1998). 
 
2.3 Fatigue 
 
Fatigue is defined as a decrease in force production in the presence of increased 
perception of effort (Enoka & Stuart 1992). Since fatigue is a limitation to high-intensity 
exercise performance, minimizing fatigue and / or delaying the onset of fatigue is 
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desirable during competition. When energy needs are met primarily through anaerobic 
metabolism, several processes occur which lead to fatigue. The increase in H+ 
concentration causes: i) an impaired release of calcium from the sarcoplasmic reticulum 
of the muscle cell, ii) an inhibition of the coupling between actin and myosin (Fits 1994, 
Noakes 2000, Requena et al. 2005, Wells et al. 2009), iii) a decrease in the rate of 
glycolysis through an inhibition of a pH sensitive enzyme phosphofructokinase (PFK), the 
rate-limiting enzyme in the glycolytic pathway (Noakes 2000),  iv) a reduction in ATP 
production (Fitts 1994), v) a reduction in the ATP utilization rate (Fitts 1994), and vi) a 
decrease in pH sensitive transporter activity, e.g., monocarboxylate lactate transporter 
(Wells et al. 2009), KATP transporter (Street et al. 2005).  
Additionally, skeletal muscle releases potassium ion (K+) during activity. K+ 
accumulation reduces muscle excitability and is considered to be involved in both the 
development of muscle fatigue and blood flow regulation (Fitts 1994, Sostaric et al. 
2006, Street et al. 2005). The capacity for K+ re-uptake via the Na+/K+ pump and 
Na+/K+/Cl- co-transporter is exceeded during anaerobic exercise. Consequently, K+ 
accumulates in the interstitium and plasma (Sostaric et al. 2006, Street et al. 2005).  
 
2.4 Enhancement of Performance in Sport 
 
Since fatigue is a limitation to high-intensity performance, its delay is desired during 
competitions. Ergogenic aids provide enhanced energy production, utilization, and 
recovery during competition in the form of a drug, natural health product, or other 
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intervention (Aherendt 2001). Products that claim to be performance enhancing are 
popular with recreational and elite athletes alike. However, due to the negative side 
effects of doping and banned substances, many athletes are now turning to ergogenic 
supplements as a safe and legal way to boost athletic performance. 
Currently, athletes appear to be searching for legal alternatives; particularly 
nutritional ergogenic aids (Williams 1995). Nutritional ergogenic aids encompass a broad 
range of substances that include standard dietary constituents, like carbohydrates and 
proteins to atypical substances, such as sodium bicarbonate and creatine (Applegate 
1999).   
 
2.5 Alkalizing Agents 
 
During anaerobic type maximal exercise (such as a 200-meter freestyle race), pH 
within the blood can decrease from 7.4 to 7.1, while muscle pH can decrease to as low 
as 6.8 (McNaughton et al. 2008). Muscle physiology has defense mechanisms that 
support the cell to keep pH in an acceptable range. Essentially this involves decreasing 
the concentration of intracellular free H+ through intracellular mechanisms and 
extracellular buffering systems that favor the movement of H+ between the muscle cell 
and the extracellular fluid.  Throughout the body, strategies exist to offset the increased 
production of H+ during maximal exercise such as i) acid excretion by the kidney (Oster 
et al. 1988), ii) hyperventilation during breathing (Wells et al. 2005), and iii)  blood 
bicarbonate buffering (Requena et al. 2005). 
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The use of substances to buffer the production of H+ during anaerobic type 
sporting competitions has gained in popularity for a number of years. Ingesting alkalizing 
agents has been suggested as a strategy to postpone the onset of fatigue during high 
intensity exercise by slowing the decline in muscle and blood pH (Katz et al. 1984, 
Kowalchuk et al. 1989). Studies have confirmed (Ibanez et al. 1995, Katz et al. 1984, 
McNaughton 1990, Robergs et al. 2005, Sostaric et al. 2006) that increasing extracellular 
pH, via an alkalizer, promotes the efflux of Lactate and H+ from active muscles compared 
to placebo. Therefore, artificially inducing alkalosis prior to anaerobic exercise may 
reduce intracellular acidosis and increase the time to fatigue (McNaughton et al. 2008, 
Noakes 2000). 
Currently, the process known as “bicarbonate loading” in which sodium 
bicarbonate is ingested pre-performance, is a popular method of blood alkalization with 
athletes. Numerous studies have examined the impact of sodium bicarbonate on 
performance in a broad array of modalities, distances, times, and doses. Indeed, a meta-
analysis done by Carr et al. (2011) revealed sodium bicarbonate enhanced performance 
by 1.7% (±2.0%) for a 60s maximal effort, with a dose of 0.3g/kg of body mass being the 
optimal dose. However, the side-effects associated with ingesting the high doses 
needed to induce an adequate modification of the acid-base state, can be detrimental 
to performance (McNaughton et al. 2008, Requena et al. 2005, Schabort et al. 2000). 
The GI acceptance profile of sodium bicarbonate is narrow and few humans can 
adequately tolerate the doses needed to elicit an ergogenic effect (Oster et al. 1988). 
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Therefore, another alkalizing agent, Na-CIT, has increasingly been studied and is 
garnering interest from coaches and athletes. 
 
2.5.1 Sodium Citrate 
 
Na-CIT has been studied in many sports over a broad array of doses, times, and 
distances with inconclusive results (Table 1). Indeed, a meta-analysis by Carr et al. 
(2011) revealed no clear effect on performance. It is this uncertainty that has prevented 
Na-CIT from becoming a viable, and improved GI accepting, alternative to sodium 
bicarbonate. 
 Na-CIT is not found in body fluids. After ingestion, Na-Cit quickly dissociates into 
sodium (Na+) and citrate (CIT) ions. The CIT anion, unlike the bicarbonate anion, is 
expelled from the plasma (Kowalchuk et al. 1989). Hence, the electrical equilibrium of 
cations and anions becomes unbalanced after ingestion. Neutrality is achieved by 
decreasing the concentration of H+ and increasing bicarbonate concentration 
(Kowalchuk et al. 1989, Requena et al. 2005). Unlike sodium bicarbonate, this process is 
an indirect method of plasma alkalization, and is posited to be derived from liver 
oxidation (Requena et al. 2005).  
The expelled CIT is capable of entering the sarcolemma (Linossier et al. 1997) 
through a recently discovered plasma membrane transporter - a plasma membrane 
citrate transporter (Sun et al. 2010). A comparison of sequence similarity, transport 
mechanisms, and types of inhibitors reveals that the plasma membrane citrate 
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transporter is distinctly different from the mitochondrial citrate transport protein (Sun 
et al 2010). Within the muscle cell, CIT is involved in several metabolic processes: i) it 
acts as a metabolic intermediary for the Krebs cycle (Wells et al. 2009), ii) it transports 
acetyl CoA from the mitochondrion to the cytosol for fatty acid synthesis (Wells et al. 
2009), iii) it is a negative allosteric effector of phosphofructokinase (PFK) (Kemp & Foe 
1983); however, this inhibitory effect may be exaggerated under normal physiological 
conditions (Peters & Spriet 1995); and iv) it can cause a reduction in the contraction 
threshold by means of its effect on the membrane’s potential (Requena et al. 2005).  
Therefore, Na-CIT seems to have a greater effect on potential performance 
enhancement than just plasma alkalization and lactate/H+ kinetics. However, the nature 
of the mechanisms involved in the delay of exhaustion could be different and remains to 
be elucidated (Linossier et al. 1997). 
 
2.6 Sodium Citrate Supplementation in Athletes  
 
The published research investigating the ergogenic effect of sodium bicarbonate has 
reached the general conclusion that it aids in maximal intensity performance. However, 
Na-CIT is still in the experimentation phase of study, and at present, results point 
toward an unclear effect on performance. Though both substances have paralleled 
physiological behavior, the optimal protocol for each substance to elicit enhanced 
performance differs widely.  
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2.6.1 Finding the Optimal Protocol 
 
McNaughton (1990) pioneered finding the optimal protocol to elicit an ergogenic effect 
with Na-CIT. He investigated whether administration of Na-CIT would enhance 
performance and if so, what would be the optimal dose to improve anaerobic 
performance in a 60s sprint. Using the doses 0.1 - 0.5g/kg of body mass in 0.1g/kg 
increments, 90min pre-trial, McNaughton tested the outcome variables of peak power 
and total work on a cycle ergometer. The minimal dose to bring about an improvement 
over control and placebo was 0.3g/kg with the optimal dose being 0.5g/kg (P<0.0001). 
Although McNaughton (1990) tested up to 0.5g/kg, Schabort et al. (2000) investigated 
an acute dose of 0.6g/kg of Na-Cit and observed that GI discomfort negatively affected 
performance in 5 of the 8 subjects during a 40km cycling time trial. Following his 
experiment in 1990, McNaughton and Cedaro (1992) aimed to find the optimal 
durations of exercise performance to benefit from Na-Cit ingestion at 0.5g/kg, 90min 
pre-trial. The authors tested durations of 10, 30, 120, and 240s at maximal intensity on a 
cycle ergometer. Significant improvements in total work and peak power compared to 
placebo were found at 120 and 240s (P<0.05) performance durations. Therefore, the 
authors concluded that ingestion of Na-CIT at 0.5g/kg 90min pre-trial would benefit 
maximal intensity exercise lasting 60-240s. However, unlike sodium bicarbonate, Na-CIT 
must be metabolized to bring about an increase in blood pH and bicarbonate 
concentration (Kowalchuk et al. 1989, Linossier et al. 1997). With this in mind, Potteiger 
et al. (1996) discovered that peak blood pH and bicarbonate concentration for Na-CIT 
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were reached at 120min post-ingestion compared to 90min for sodium bicarbonate. 
Though there is considerable inter-individual variability with respect to metabolization 
times (Potteiger et al. 1996, Schobart et al. 2000), the consensus is that Na-CIT ingestion 
should take place 90 – 120min pre-trial. In summary, administration of Na-Cit at a dose 
of 0.5g/kg, at 120min pre-trial, is the optimal protocol to elicit a potential ergogenic 
effect during maximal anaerobic performance. 
 
 2.6.2 Sodium Bicarbonate versus Sodium Citrate 
 
Few studies have compared the effectiveness of sodium bicarbonate to that of Na-CIT 
using similar protocols (Parry-billings & Maclaren 1986, Potteiger et al. 1996, Tiryaki & 
Atterbom 1995, Van Montfoort et al. 2004). Van Montfoort et al. (2004) compared 
sodium bicarbonate, Na-CIT, sodium lactate, and sodium chloride as a placebo in a run 
to exhaustion test. The test ran at a fixed speed that was derived during a familiarization 
session in order to elicit fatigue in 1-2min. Equimolar doses were ingested relative to 
body mass (3.6mOsmol/kg) 90min prior to the performance test. Even though blood 
bicarbonate values were highest for the CIT group, and were significantly increased over 
placebo, the sodium bicarbonate test revealed the greatest percentage of mean 
improvement at 2.7%, with 1.7% and 0.5% being reported for sodium lactate and Na-
CIT, respectively. The authors reasoned that the high dose of 0.5g/kg of CIT may have 
inhibited ATP production through its effect on PFK compared to a common lower dose 
of 0.3g/kg. Unfortunately, the only data analysis done by Van Montfoort et al. consisted 
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of calculating percent mean improvement and percent chance of improvement when 
comparing the buffering agents (Table 1). Parry-Billings & MacLaren (1986) used doses 
of 0.3g.kg for both sodium bicarbonate and Na-CIT, as well as a combination of the two, 
and found no significant change in total work compared to placebo for 3 intermittent 
Wingate tests. However, the CIT trial did have the highest pH and bicarbonate 
concentration compared to sodium bicarbonate, which may have contributed to a 
higher mean and peak power in the second and third bouts. When comparing sodium 
bicarbonate (0.3g/kg) to Na-CIT (0.5g/kg) in terms of aerobic capacity, Potteiger et al. 
(1996) reported no difference between conditions. However, the authors suggested that 
it would be better to test athletes for a set distance or in a time trial than to use a set 
run velocity to exhaustion, as was the case here. The authors argued that based on the 
higher blood lactate in the CIT trial, if run velocity could change voluntarily, the greater 
efflux of H+ from the cell due to the pH contrast could lead to an increased speed and 
greater power for the given amount of time.  
 
2.6.3 Acute Effects during High-Intensity Sport Specific Exercise  
 
McNaughton & Cedaro (1992) reported an ergogenic benefit of Na-Cit ingestion in 
cycling when recording total work and peak power output for durations of 60 - 240s 
(P<0.05) at a dose of 0.5g/kg. However, no ergogenic effect was observed for exercise 
durations of 10 - 30 seconds. Similarly, Linossier et al. (1997) reported time to 
exhaustion when cycling at 120% peak VO2 was significantly extended. Interestingly, the 
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authors reported a large variability in response to CIT (1 - 44%), which was considered to 
be associated with the differences in the physical conditions of the subjects. Those with 
a lower peak VO2 actually responded better than the more endurance trained subjects. 
Contrary to this observation, Shave et al. (2001) tested elite runners in a 3000m time 
trial, and reported a significant performance enhancement (P<0.05) during the CIT trial. 
Also in line with the study done by McNaughton & Cedaro (1992), Ibanez et al. (1995) 
tested six elite 400m runners in a 300m time trial. Though there was a significant peak in 
blood lactate concentration compared to placebo during recovery (P<0.01), no 
significant performance enhancement was reported between the CIT and placebo 
groups. The authors suggested that the higher blood lactate concentration, without the 
subsequent improvement in performance, may be due to an increased efflux via the pH 
contrast or due to a decreased uptake by working muscle. In the case of the latter, it 
was reasoned that H+ may not be the main factor effecting rate limiting enzymes, but 
instead, “a change in the concentration of electrolytes which limit excitation contraction 
coupling would reduce the muscles’ ability to produce tension.” Therefore, alkalosis 
could lead to a decreased efflux of electrolytes from the cell, maintaining homeostasis 
and production of energy (Street et al. 2005). Furthermore, Zochowski et al. (2009) 
compared two unique administrations of Na-CIT (chronic and acute), each at the same 
dose of 0.3g/kg, to placebo in elite swimmers. Perhaps not surprisingly, considering the 
doses of Na-CIT administered, no significant treatment effects were found compared to 
placebo. It is important to note that this is the only study that has investigated the 
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potential effects of chronic ingestion of a lower level Na-CIT over a longer period of time 
to minimize the potential GI upset that follows in some cases of acute dosing. 
There have been a few studies that analyzed the potential benefits of Na-CIT in 
long-term high intensity exercise with conflicting results (Kowalchuk et al. 1989, Oopik 
et al. 2003, Oopik et al. 2004, Potteiger et al. 1996, Schabort et al. 2000). Three of these 
studies (Oopik et al. 2003, Oopik et al. 2004, and Potteiger et al. 1996) found 
noteworthy effects. In a controlled environment, Oopik et al. (2003) found an 
improvement in 5km run performance (P = 0.01) on a treadmill at a dose of 0.5 g/kg 
taken 120min pre-performance. The same researchers, however, performed the same 
experiment as a field study and reported a lack of improvement between treatments, 
which they attributed to environmental factors, such as wind (Oopik et al 2004). 
Potteiger et al. (1996) recorded a 4% improvement in 30km cycling time (P<0.05) and a 
significant increase in blood lactate concentration post-exercise (P<0.01). There was no 
difference between treatments in power output over 30km; however, in the first 25min, 
the power output for the CIT trial was higher. Blood gas measurements were also 
recorded, but were not significantly different across treatments. According to the 
authors, these data are important for two reasons: “1) PO2 similarity for the two trials 
indicates that oxygen delivery was consistent and the higher blood lactate concentration 
was not the result of a lack of oxygen, and 2) the lack of differences of PCO2 indicates 
that any excess carbon dioxide formed as a result of buffering the excess H+, via 
carbonic anhydrase reaction, was ventilated” (Potteiger et al. 1996). In contrast, both 
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Schabort et al. (2000) and Kowlachuk et al. (1989), following different dosing protocols, 
reported a lack of improvement in both power output and time between treatments. 
Research into the effect of alkalizing agents in females is limited and the results 
suggest that the effect is negligible. Two studies investigated the potential for an 
ergogenic effect with Na-CIT, and in both cases no significant differences in time were 
reported. The investigations chose well-trained runners, with Oopik et al. (2008) 
reporting 1500m run times and Tiryaki and Atterbom (1995) assessing 600m run times 
on an outdoor track. Contrary to most other published research (Ibanez et al. 1995, 
Kowalchuk et al. 1989, Linossier et al. 1997, McNaughton 1990, Robergs et al. 2005, 
Oopik et al. 2003), blood lactate concentration was unchanged between trials. Although 
there are ethical considerations when administering a natural health product to women, 
more study should be done to elucidate the potential that alkalizing agents could have 
on women in sport. 
Most of the studies mentioned above, however, have reported considerable 
limitations that may contribute to the ambiguous results found. First, most studies in 
well-trained athletes have a small sample size, resulting in a lack of power for adequate 
statistical analysis. Other confounding variables, such as wind speed, temperature, and 
altitude, may have also contributed to differences in results (Tiryaki et al. 1995). 
Furthermore, in cases where improvement was minimal and non-significant, the 
argument can be made that any improvement in elite sport would be decisive in 
competition (Freiche et al. 2002). Second, CIT is an inhibitor of PFK, possibly inhibiting 
ATP production at higher doses (Kowalchuk et al. 1989, Oopik et al. 2008). In addition, 
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during longer-term high intensity exercise, factors such as hydration and electrolyte 
balance may also play significant roles in determining performance outcomes (Linossier 
et al. 1997). Third, administering Na-CIT with the correct pre-performance protocol is 
necessary in eliciting the potential ergogenic effects that the buffering agent may offer 
(McNaughton 1990, McNaughton & Cedaro 1992). Moreover, alkalizing agents may not 
be well tolerated, especially at higher doses, causing GI discomfort, which may be 
detrimental to performance (Schabort et al. 2000). 
 
2.6.4 Intermittent Exercise 
 
There are very few studies on repeated bouts of exercise with Na-CIT supplementation 
(Davidson et al. 2004, Cox & Jenkins 1994, Van Someren et al. 1998), and the results are 
not as convincing as those found when sodium bicarbonate is administered 
(McNaughton et al. 2008). A review done by McNaughton et al. (2008) summarized 
recent literature on the effect of sodium bicarbonate during multiple bouts of exercise 
and found 3 of 5 of the studies reported improvements in performance. In contrast, 
none of the three studies administering Na-CIT recorded any improvement (Table 1).  
 
2.6.5 Effects on Cardio-Respiratory Performance 
 
Cardio-respiratory performances tend to show a net benefit with Na-CIT 
supplementation (Frieche et al. 2002, Hauswirth et al 2005, Jain et al. 2003). Hauswirth 
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et al (2005) reported a significant improvement in muscle endurance during isometric 
knee extension in normoxia (P<0.05), and a non-significant improvement in hypobaric 
hypoxic conditions (463mmHg, 61.7kPa). In a sport specific study, Frieche et al. (2002) 
reported a trend toward significance when cycling to exhaustion at 112% of VO2max in 
normoxia (P = 0.09). This represents an improvement of about 9s compared to placebo, 
which would be decisive in competition. In addition, significant improvements were 
reported in ventilation rate (VE) (P<0.018), rate of elimination of CO2 (P<0.0007), and 
respiratory exchange ratio (RER) (P<0.01) in both normoxia and hypoxia (2320m). These 
data suggest that the intake of an alkalizing agent attenuates ventilation rates and aids 
in elimination of CO2. It is possible that a central control prevails over peripheral 
regulatory mechanisms controlling VE, allowing a decreased VE during a state of 
increased pH due to alkalization by Na-CIT. Another possible explanation for the 
reported decearse in VE may be to a drop in sympathetic activity. However, research 
suggests that ingestion of an alkalizer does not alter sympathetic activity, during or post-
exercise, compared to placebo (Bracken et al. 2005, Marx et al. 2002). Taken together, 
this is an important observation when considering the example of swimming where 
athletes must sustain a high rate of energy expenditure while suspending breathing for 
20 - 30% of their race (Craig 1986). 
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2.6.6 Effects on Recovery 
 
The recovery kinetics of acid-base balance is important when addressing training or 
sporting events requiring multiple sprint/recovery bouts. Robergs et al. (2005) observed 
that the recovery kinetics of acid-base balance have not addressed adequate durations 
of recovery (15min compared to 60min). This applies to sporting events, such as 
swimming or judo, where multiple performances are done during any given competition 
session, usually over a period of a couple hours. Therefore, the authors investigated 
blood pH, bicarbonate, and lactate recoveries comparing ammonium chloride, sodium 
bicarbonate, Na-CIT, and placebo. Consistent with the literature, peak blood pH, 
bicarbonate, and lactate concentrations, were observed in the alkalotic condition. 
Recovery was separated into two segments for pH: 1) 0 - 15min and 2) 15 - 60min. The 
first recovery segment revealed similar recovery slopes for all conditions, but the 
ammonium chloride and placebo trials had a significantly lower blood pH than the 
alkalotic trial (P<0.05). The second recovery segment followed a similar pattern with the 
alkalotic condition maintaining an overall higher pH. These findings were also reported 
by Jain et al. (2003). Furthermore, these authors investigated the recovery dynamics of 
oxygen deficit incurred at the onset maximal exercise. They reported that CIT reduced 
post-exercise oxygen debt incurred (P<0.01) following cycling at a set resistance to 
exhaustion. 
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2.7 Swimming 
 
Competitive swimming provides an ideal model for the characterization of the anaerobic 
response and by extension alkalizing agents. Events range in duration from 22s (50m 
freestyle) to 15min (1500m freestyle) with the highest blood lactate concentrations 
found in the 200m (2min) event. Typical post-race blood lactate concentrations for 
these events are 6.4, 9.1, and 14.0mmol/L in the 1500m, 50m, and 200m events 
respectively (Vescovi et al. 2011).  Furthermore, swimmers often race several events 
within 30 - 90min during any given session. Swimmers must also contend with 
restrictions placed on their breathing frequency during intense exercise, resulting in a 
unique interaction between muscle physiology, technique, and ventilation. Exercise 
hyperpnoea is limited during high intensity swimming because turning or lifting the 
head to breathe may jeopardize execution of proper stroke technique (Wells et al. 
2005). During high intensity swimming, breath holding can result in significant decreases 
in the arterial partial pressure of oxygen (PaO2), decreased blood pH, but an unchanged 
arterial partial pressure of carbon dioxide (PaCO2) relative to non-frequency controlled 
breathing (PaO2 unchanged, pH unchanged, PaCO2 decreased) (Sharp et al. 1991). 
Indeed, swimming requires that the athlete sustain a high rate of energy expenditure 
and the suspension of breathing for approximately 20 - 30% of a race (Craig 1986). Given 
these limitations and the physiological consequences, it is likely that anaerobic 
metabolism is a significant contributor to metabolic power in competitive swimming, 
and may also be a primary determinant of fatigue and limitations in performance 
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(Noakes 2000). Therefore, administration of an alkalizing agent may potentially enhance 
performance by a greater magnitude than in cycling or running. 
 
2.8 Side Effects of Sodium Citrate Ingestion 
 
Both sodium bicarbonate and Na-CIT can induce to GI upset, cramps, or diarrhea and 
may not be tolerated well by all athletes. It has been suggested that approximately 10% 
do not tolerate these substances well (McNaughton et al. 2008). When Na-Cit is 
consumed, there is a possibility that these symptoms may be due to an increased 
osmolality of the GI tract and water may be shifted from the plasma to the intestine to 
counteract the hypertonicity (Requena et al. 2005). However, Na-CIT solutions are 
preferred to sodium bicarbonate. This is because, with a few exceptions (Cox and 
Jenkins 1994, Schobart et al. 2000), Na-CIT is associated with an improved GI acceptance 
profile. Nonetheless, there seems to be a direct relation between the appearance of 
these side symptoms and the dose administered, although high doses are needed to 
adequately modify the acid-base balance (McNaughton 1990). Attaining peak buffering 
potential, while minimizing the risk of GI distress before racing, is essential because 
performance may be negatively affected (Schabort et al. 2000). Pre-race 
experimentation is suggested as a prudent strategy as it could decrease the chance of 
the occurrence and severity of GI distress. In this respect, some researchers have 
experimented with allowing the intake of water ad libitum after supplying an alkalotic 
solution. While some studies have modified the administration of Na-CIT using capsules, 
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this presents the problem that a large number must be ingested. 
 
2.9 Conclusion 
 
In most cases, alkalizing agents seem to provide a benefit to sport performance, but the 
data on the effects of Na-CIT in high performance athletes is unclear. It was concluded 
by Carr et al. (2011), that the variability in response may be due to inconsistent 
methodology. Indeed, consistent adherence to a standard protocol has been an issue 
when investigating Na-CIT (Table 1). Nonetheless, the general consensus is that there is 
a performance enhancing effect with ingestion of Na-CIT. Therefore, more research with 
consistent methodology is recommended to elucidate the potential ergogenic effect of 
Na-CIT. In addition, there is a gap in the literature with respect to the study of young 
well-trained athletes who also participate in multi-event sports like swimming. 
Table 1: A complete list of current literature pertinent to sodium citrate in sport and exercise as of February 2013 
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Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
         Single Bout 
         
Ibanez et al. 1995 6 elite 
runners 
male outdoor track 300m 0.5 180 p>0.05 (35.43 ± 1.19, 35.55 ± 1.18s; 
CIT, PLC) 
Kowalchuk et al. 
1989 
9 active 
students 
 cycle ergometer 20min 
33%, 
20min 
66%, 95% 
VO2max to 
exhaustion 
0.3 60 p>0.05 (310 ± 69, 313 ± 74s; CIT, 
PLC) 
Linossier et al. 1997 5+3 moderately 
active 
students 
male + 
female 
cycle ergometer 120%VO2 
peak to 
exhaustion 
0.5 90 p<0.05 (297 ± 29, 258 ± 29s; CIT, 
PLC) 
McNaughton & 
Cedaro 1992 
10 active 
students 
male cycle ergometer 10, 30, 120, 
240s 
0.5 90 p<0.05 (Total Work and Peak 
Power: 120 and 240s: ; compared to 
Control and PLC) 
McNaughton 1990 11 active 
students 
male cycle ergometer 60s 0.1, 0.2, 
0.3, 0.4, 
0.5 
90 p<0.05, p<0.001, p<0.0001 (Total 
Work and Peak Power: 0.3, 0.4, 0.5; 
compared to Control and PLC) 
Oopik et al. 2003 17 well-trained 
runners 
male treadmill 5km 0.5 120 p=0.01 (1153.2 ± 74.1, 1183.8 ± 
91.4s; CIT, PLC) 
Oopik et al. 2004 10 well-trained 
runners 
male outdoor field 5km 0.5 120 p=0.09 (1100.0 ± 79.1, 1082.7 ± 
62.0s; CIT, PLC) 
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Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
Oopik et al. 2008 17 well-trained 
middle 
distance 
runners 
female outdoor track 1500m 0.4 90 p>0.05 (321.4 ± 26.4, 317.4 ± 22.5s; 
CIT, PLC) 
Potteiger et al. 1996 8 well-trained 
cyclists 
male cycling 
ergometer 
30km 0.5 90 p<0.05 (3459.6 ± 97.4, 3562.3 ± 
108.5s; CIT, PLC) 
         Schabort et al. 2000 8 well-trained 
cyclists 
male Mounted 
personal bicycle 
40km 0.2, 0.4, 
0.6 
60 p=0.886 (power output), p=0.754 
(time)  
Shave et al. 2001  7+2 elite 
athletes 
male + 
female 
outdoor track 3000m 0.5 60 p<0.05 (610.9 ± 36.6, 621.6 ± 31.4s; 
CIT, PLC) 
Street et al. 2005 7 active male one leg knee 
extension 
constant 
load (W) at 
60RPM to 
exhaustion 
0.3 150 p=0.1 (418 ± 57, 356 ± 23s; CIT, PLC) 
Zochowski et al. 
2009 
7 elite 
swimmers 
 25m pool SC 200m Chronic: 
4 days x 
0.3, 
Acute: 
0.3 
90 p>0.05 (125.8 ± 7.2, 125.4 ± 7.1, 
125.7 ± 8.1; Chronic, Acute, PLC) 
         
         
32 
 
Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
         Multiple Bouts 
         
Cox & Jenkins 1994 8 moderately 
active 
students 
males cycle ergometer 5 x (60s + 
5min 
recovery) 
0.5 90 (141.8 ± 6.9, 142.2 ± 6.2 KJ; CIT, 
PLC) 
Davidson et al. 2004 9 recreational 
athletes 
 isokinetic knee 
extension/flexion 
75˚/sec 
5x (10 reps 
+ 1min 
recovery) 
0.3 75 Total work set one/five: 312/221, 
287/200 KJ; CIT, PLC 
Van Someren et al. 
1998 
9 + 3 active non-
athletes 
male + 
female 
cycle ergometer 5 x (45s + 1 
min 
recovery) 
0.3 90 p>0.05 (Total Work and Peak 
Power) 
Oxygen Debt 
         Jain et al. 2003 10 untrained male cycle ergometer 2kg friction  
fixed pedal 
rate to 
exhaustion 
0.5 120 p<0.01 (O2 debt: 4.56 ± 0.66, 7.77 ± 
0.96L; CIT, Control) 
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Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
         Hypoxia 
         
Freiche et al. 2002 17 students male cycle ergometer 112% 
VO2max at 
No or H 
(2320m) 
0.4 120 p<0.018 (VE lower), p<0.0007 
(VCO2 higher), p<0.0119 (RER 
higher), with CIT in both No and H. 
Hausswirth et al. 
1995 
8 healthy male isometric knee-
extension 
35% MVC 
at No or 
HH 
(463mmHg, 
61.7kPa) 
0.4 120 p<0.05 (muscle endurance: 192 ± 
17, 156 ± 17; No + CIT, No + PLC) 
Non-significant increase in 
endurance for HH (168 ± 15, 145 ± 
10; HH + CIT, HH + PLC) 
         
Catecholamine Response 
         
Bracken et al. 2005 8 healthy male cycle ergometer 2min 110% 
VO2max 
0.5, 0.3 60 Plasma [DA], [NE], and [EPI] were 
unaltered with CIT 
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Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
         Diet Manipulation 
         
Ball & Maughan 
1997 
6 healthy male cycle ergometer 100% 
VO2max to 
exhaustion 
Normal 
or h-CHO 
diet: 
3days + 
0.3 CIT 
180 No difference: 202 ± 23, 201 ± 16, 
205 ± 24, 204 ± 12s; N + CIT, h-CHO 
+ CIT, Normal + PLC, h-CHO + PLC 
         
Fluid and Electrolyte Regulatory Hormones 
         
Oopik et al. 2010 13 well-trained 
runners 
male treadmill running 
test to 
exhaustion 
0.5 120 p=0.003 (ALD lower in CIT post 
ingestion 
         
Recovery 
         
Robergs et al. 2005 12 well-trained 
cyclists 
male cycle ergometer 110% 
VO2max to 
exhaustion 
0.3 NH4Cl 
vs. 0.2 + 
0.2 
NaHCO3 + 
CIT 
60 p<0.05 (improved pH recovery), 
p<0.05 (post exercise acidosis: pH 
7.15 ± 006, 7.21 ± 0.007, 7.16 ± 
0.06; NH4Cl, NaHCO3+CIT, PLC) 
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Author N Subjects Gender Exercise Mode Duration 
Dose 
(g/kg) 
Load 
Time 
(min) 
P-value (outcome variable) 
         Comparison 
         Parry-Billings & 
MacLaren 1986 
6 active 
students 
male cycle ergometer 3 x (30s 
Wingate 
Tests + 
6min 
recovery) 
0.3 
NaHCO3, 
NaHCO3 + 
CIT, CIT, 
NaCl 
150 Total work over 3 tests 103%, 102%, 
101%; CIT, NaHCO3 + CIT, NaHCO3 
over PLC 
Potteiger et al. 1996 7 well-trained 
runners 
male treadmill 30min at 
lactate 
threshold 
→ 110% to 
exhaustion 
0.3 
NaHCO3 
vs. 0.5 
CIT 
120 287 (SEM 47.4), 172.8 (SEM 29.7), 
222.3 (SEM 39.7)s; NaHCO3, CIT, 
PLC 
Tiryaki & Attebom 
1995 
11+4 well-trained 
track 
athletes and 
trained non-
athletes 
female outdoor track 600m 0.3 
NaHCO3, 
0.3 CIT 
150 (121.5, 119.9, 120.4s; NaHCO3, CIT, 
PLC) 
Van Montfoort et 
al. 2005 
15 well-trained 
endurance 
runners 
male treadmill exhaustion 
~80s 
0.3 
NaHCO3, 
0.525 CIT, 
0.4 
NaLac, 
0.209 
NaCl 
90 NaHCO3:NaCl 2.7% improvement; 
CIT:NaCl 0.5% improvement. (82.3, 
78.2, 80.2, 120.4s; NaHCO3, CIT, 
Lactate, PLC) 
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ALD = Aldosterone 
CIT = Sodium citrate 
DA = Dopamine 
EPI = Epinephrine 
H = Hypoxia 
HH =  Hypobaric hypoxia 
h-CHO = High carbohydrate 
NaLac = Sodium lactate 
Lac = Lactate 
MVC = Maximal voluntary contraction 
NaCl = Sodium chloride 
NaHCO3 = Sodium bicarbonate 
NH4Cl = Ammonium chloride 
NE = Norepinephrine 
No = Normoxia  
PLC = Placebo 
RER = Respiratory exchange ratio 
VE = Ventilation 
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Chapter 3: Methods 
 
3.1 Participants 
 
Ten, well-trained, male, adolescent swimmers (mean ± SEM, age 14.9 ± 0.4 years; body 
mass 63.5 ± 4kg) participated in the current study. Participants were recruited through 
team announcements from competitive swimming clubs in the area.  A letter of 
invitation was handed out to participants that fit the study population inclusion criteria 
(male swimmers who have achieved at least regional standards). A study investigator 
was there to answer questions. Participants (and their parent or guardian) provided 
written informed assent and consent. Participants were asked to refrain from abnormal, 
energy consuming lifestyle choices between the four swimming trials. Participants 
refrained from using caffeine and alcohol during the day of each trial. All procedures 
were approved by Health Canada Natural Health Products Directorate and Brock 
University Research Ethics Board (Protocol: 12-009).  
  
3.2 Experimental Design 
 
The current study was performed using a randomized, double-blinded, placebo 
controlled, cross-over design. All participants performed four swimming trials under 
four treatment conditions determined by the amount of, and time over which, sodium 
citrate dihydrate was ingested. Specifically, all participants randomly performed 2 
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experimental trials: 1) acute (ACU), 2) chronic (CHR), and 2 placebo trials: 3) acute 
placebo (PLC-A), and 4) chronic placebo (PLC-C). The participants were randomly 
assigned by computerized random number generator. The study was conducted during 
the mid-season period of training in a 4 week period without a competition to minimize 
training and tapering effects. Each Na-CIT trial was separated by at least a 6 day 
washout period.  
 
3.3 Sodium Citrate Dihydrate and Placebo Loading Protocol 
 
The placebo and Na-Cit were delivered in a solution of 500mL of Crystal Light Pink 
Lemonade flavoured water. Ten adult volunteers tested multiple flavours to find an 
optimal masking flavour of Na-CIT in an effort to ensure blinded supplementation. The 
ACU involved taking 0.5g/kg of body mass of Na-CIT in solution with 500mL of flavoured 
water 120min pre-performance. The CHR involved taking 0.1g/kg of body mass of Na-CIT 
three times per day for 3 days and on the 4th day a dose of 0.3g/kg of body mass, 
120min pre-performance. The PLC-A and PLC-C had 500mL of flavoured water in equal 
amounts and frequency as their corresponding experimental trial. The placebo and Na-
Cit bottles were coded by an independent researcher, and the key was used only at the 
time of data analysis at the end of the study by the primary researcher. During every 
trial, swimmers were asked anecdotally if they knew which solution they were ingesting 
and if they were experiencing any GI discomfort. 
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3.4 200m Swim Trials 
 
The 200m swim trials were conducted at Brock University in a short-course (25m) pool. 
Each participant swam a 200 metre long event in a stroke of their choosing at maximal 
effort each trial day. The choice of stroke was given to increase participant motivation 
and create a near real life setting. For each swimmer, the same stroke was used for all 
four trials (backstroke n = 1, breaststroke n = 2, freestyle n = 7, individual medley n = 1). 
All swimmers wore their regulation competition apparel for each trial. Warm-up and 
warm-down procedures were based solely on each swimmer’s typical regimen for 
competition. Every trial was done during the same time of the day (5:00 - 6:00pm) in 
order to minimize diurnal and daily variations. The 200m swim began with a dive from 
the blocks initiated by the same starter’s “take your marks, and go.” Swimmers` times 
and rates of perceived exertion (RPE) were recorded at the end of each trial. All 
performance times were recorded with a manual stopwatch by the same investigator. 
 
3.5 Blood Sampling and Analysis 
 
Blood was collected pre-ingestion, 100min post-ingestion (20min pre-trial), and 3min 
post-trial. A venous blood sample was collected by finger prick and analyzed 
immediately by an automated lactate analyzer (Arkray Lactate Pro LT-1710) to 
determine whole blood lactate. Blood lactate has been measured following post-
exercise at 0min, 2min, 3min, 5min, and 10min time points with the highest 
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concentrations recorded between 3 - 5min post-exercise (Vescovi et al. 2011, Frieche et 
al. 2002, Bangsbo et al. 1994, Rimaud et al. 2010). With the same finger prick, ~95μL 
blood was collected into a plain capillary tube and immediately analyzed for base excess 
(BE), pH, bicarbonate, and PCO2 by i-STAT 1 Analyzer (Abbott Point of Care). Blood 
collection was done by the same two researchers for each trial. 
 
3.6 Statistical Analysis 
 
The approach to the calculation of sample size depends on the complexity of the study 
design. Using traditional statistics, sample size is calculated from known measures of 
central tendency and variability related to an expected difference that has biological 
significance. The only factor in these cross-sectional study designs that can be 
manipulated to increase power is the sample size. However, with repeated 
measurements, such as in the present study, it is possible to take into account the 
repeated observations within an individual in the sample size estimate. Increasing the 
number of repeated observations will reduce the required sample size because the 
within individual variance is reduced. In practice, when looking for a given absolute 
difference, smaller sample sizes are therefore needed for repeated measures studies 
compared with cross-sectional studies.  With this in mind, we used Cohen’s d (Cohen 
1992) of moderate to large effect sizes (d = 0.65-1.02), along with the pre- and post-trial 
blood lactate measurements from a published 5 km run study in adults (Oopik et al. 
2003) to detect between trial differences with a power of 0.80 and alpha at 0.05. This 
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resulted in a sample size of 8. It would, therefore, seem reasonable to recruit 10 
subjects to allow for a 10% drop out rate, yet maintaining adequate power.  
 The Statistical Package for Social Sciences (SPSS Inc., Version 19.0) was used for 
data analyses and statistical significance was accepted at p<0.05. Time and lactate 
concentrations were analyzed with paired t-tests for direct desired comparisons. RPE 
was analyzed with a repeated measures ANOVA to establish equal effort between all 
trials. Due to data collection issues, leading to a few missing data points, BE, 
bicarbonate, pH, and PCO2 were analyzed as a between groups ANOVA and the 
assumption of equal sample sizes was not satisfied. This was accounted for in simple 
comparisons by using a Gabriel’s post-hoc when the ANOVA yielded a significant effect.  
Data were analyzed for the potential of finding “responders” and “non-
responders.” If participants had a greater than 0.4% improvement, which corresponds 
to a significant competitive improvement, in ACU versus PLC-A, then they were 
considered responders. The 0.4% improvement in swimming performance was derived 
by analyzing the magnitude of improvement needed to medal at the Olympics when a 
swimmer is ranked in the Top 10 in the World (Pyne et al. 2004, Trewin et al. 2004).  
Estimating the practical significance of observed effects overcomes a potential limitation 
of statistical significance where an outcome is assessed as non-significant (P > 0.05) but 
is of sufficient magnitude to be practically or clinically important.   
 Of the ten swimmers, five were identified as responders. Anthropometric data 
were compared between responders and non-responders for differences in age and 
body mass using an independent sample T-test. Due to small sample size, responders 
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did not satisfy the assumptions of normality for time and lactate concentrations and 
were analyzed with a non-parametric Wilcoxon Signed Ranks test. Lactate 
concentrations of responders and non-responders were compared using a Mann-
Whitney U test.  
 
Chapter 4: Results 
 
4.1 200m Swim Trials 
 
Anthropometric data are presented in Table 2. The PLC-A and PLC-C trials had the same 
mean performance times (143.5 ± 4.7, and 143.5 ± 5.4s for PLC-A and PLC-C, 
respectively) proving that the young swimmers were able to accurately reproduce their 
performance. Mean performance time was also not different across the four trials 
(143.5 ± 4.7, 143.9 ± 5.4, 143.7 ± 5.4, 143.5 ± 5.4s for PLC-A, ACU, CHR, PLC-C, 
respectively). When comparing PLC-A versus ACU, PLC-C versus CHR, and ACU versus 
CHR no significant differences were found (P = 0.62, 0.89, and 0.75, respectively) (Fig. 1). 
Furthermore, RPE was not statistically different across all trials (F = 0.75, P = 0.53, Ƞ2 = 
0.77) (Fig. 2). 
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Figure 1: Mean ± SEM 200m swimming time of the 10 participants for each trial. 
 
 
Figure 2: Mean ± SEM RPE of the 10 participants for each trial.  
 
 
Data were analyzed for the potential of finding “responders” and “non-
responders.” Of the ten swimmers, five were identified as responders (136.4 ± 7.4, 
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135.0 ± 7.6, 135.2 ± 7.2, 136.2 ± 8.7 for PLC-A, ACU, CHR, PLC-C, respectively) with a 
significant improvement of 1.03% in the ACU compared to the PLC-A trial (P = 0.048) 
(Fig. 3). However, there were no significant differences when comparing CHR versus 
PLC-C (P = 0.89) and ACU versus CHR (P = 0.2). There was no significant ergogenic or 
ergolytic effect found in the non-responders. Responders were characterized with a 
non-significant higher mean age (15.4 vs. 14.4yrs) (P = 0.27) and body mass (67.4 vs. 
59.3kg) (P = 0.33) compared to the non-responders (Table 2). 
 
 
Figure 3: Absolute change in performance time for the responders (n = 5) and 
non-responders (n = 5) comparing acute (ACU) versus acute placebo (PLC-A) 
supplementation trials. Performance was significantly different in the ACU versus 
PLC-A (P = 0.043). Each line represents a different swimmer. 
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Table 2: Physical characteristics (mean ± SEM) of all 10 participants, 5 responders and 5 
non-responders. 
 
 Age (yrs) Body Mass (kg) BMI (kg/m2) 
All        14.9 ± 0.4 63.5 ± 4.0 21.0 ± 0.6 
Responders 15.4 ± 0.5 67.4 ± 4.1   22.1 ± 1.1 
Non-Responders 14.4 ± 0.4 59.3 ± 3.8 19.8 ± 0.6 
 
 
4.2 Lactate Concentrations 
 
As expected, lactate concentration was significantly different from basal or post-
ingestion to post-trial (P = 0.0001) across all trials. There were no significant differences 
post-race values between trials (P = 0.1, 0.26, 0.31: PLC-A versus ACU, CHR versus PLC-C, 
ACU versus CHR) (Fig. 4). However, the responders had significantly increased lactate 
concentrations in the ACU versus PLC-A trial, but this was not the case when comparing 
the CHR versus PLC-C and ACU versus CHR trials (P = 0.048, 0.345, 0.325, respectively). 
Furthermore, responders had significantly higher lactate concentrations than non-
responders in the ACU and the CHR trials (P = 0.016, P = 0.047, respectively) (Fig. 5). 
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Figure 4: Mean ± SEM lactate concentration (mmol/L) of the 10 participants 
following basal, post-ingestion, and post-trial time points of each trial. 
 
 
 
 
Figure 5: Mean ± SEM post-trial lactate concentration (mmol/L) of responders 
and non-responders. *Significantly different (P = 0.043) from acute placebo trial 
(PLC-A). +Significantly different (P = 0.016) from non-responders in the ACU trial. 
**Significantly different (P = 0.047) from non-responders in the CHR trial. 
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4.3 Physiological Response to Na-CIT  
 
BE, bicarbonate, and PCO2 were analyzed for differences between basal, post-ingestion, 
and post-exercise. Simple effects for BE indicated significant differences between 
conditions for basal and post-ingestion values, but not for post-exercise values (F(3,21) = 
3.3 P = 0.04; F(3,18) = 21.6, P = 0.0001; F(3,14) = 1.14 P = 0.37: respectively). Post-hoc 
analysis revealed that BE in the CHR trial was significantly higher than in the ACU trial (P 
= 0.05). As was expected, BE was significantly higher in the ACU versus PLC-A trial and in 
the CHR versus PLC-C trial (P = 0.0001, P = 0.001, respectively). This did not lead to an 
attenuation in the BE decrease post-exercise compared to placebo (Fig. 6). 
 
Figure 6: Mean ± SEM base excess (BE) (mmol/L) following basal, post-ingestion, 
and post-trial time points of each trial. ^Significantly different (P = 0.05) from the 
acute trial (ACU). *Significantly different (P = 0.0001) from the acute placebo trial 
(PLC-A). #Significantly different (P = 0.001) from the chronic placebo trial (PLC-C).  
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As was expected, bicarbonate concentration was found to be significantly 
different post-Na-CIT ingestion (F(3,21) = 2.13, P = 0.13; F(3,18) = 20, P = 0.0001; F(3,14) = 1, P 
= 0.43: basal, post-ingestion, post-exercise). Na-CIT ingestion significantly increased 
bicarbonate levels in both the ACU and CHR treatment conditions compared to their 
corresponding placebo (P = 0.0001, P = 0.002, respectively). Although bicarbonate levels 
significantly increased post-exercise within each treatment condition compared to 
placebo, there was no significant difference between conditions (Fig. 7). Simple effects 
for pH indicated a significant increase for post-ingestion values (F(3,19) = 1.12, P = 0.367; 
F(3,15) = 5.14, P = 0.012; F(3,14) = 1.64, P = 0.224: basal, post-ingestion, post-exercise); 
however, post-hoc analysis results indicated a trend to significance when comparing the 
ACU trial to the PLC-A trial (P = 0.06) (Fig 8).   Furthermore, PCO2 values were not 
significantly changed between conditions (F(3,21) = 1.6, P = 0.22; F(3,18) = 1.9, P = 0.16; 
F(3,14) = 0.19, P = 0.9: basal, post-ingestion, post-exercise) (Fig. 9). 
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Figure 7: Mean ± SEM bicarbonate concentration (mmol/L) following basal, post-
ingestion, and post-trial time points for each trial. *Significantly different (P = 
0.0001) from the acute placebo trial (PLC-A). #Significantly different (P = 0.002) 
from the chronic placebo trial (PLC-C). 
 
 
 
Figure 8: Mean ± SEM pH following basal, post-ingestion, and post-trial time 
points for each trial. 
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Figure 9: Mean ± SEM PCO2 (mmHg) following basal, post-ingestion, and post-
trial time points for each trial. 
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Chapter 5: Discussion and Conclusions 
 
5.1 Discussion 
 
In this study, well-trained swimmers performed four 200m time trials at maximal effort, 
under different treatment conditions. Na-CIT was given for two dosing protocols (ACU 
and CHR), each with a corresponding placebo (PLC-A and PLC-C). When swimmers were 
asked if they knew which solution they were ingesting the response was often that they 
did not know (data not shown). This is the first study that we know of to apply a chronic 
dosing regimen to Na-CIT in an effort to improve performance and minimize GI 
discomfort. Each swimmer was asked if any GI discomfort occurred throughout the 
study and none was reported (data not shown). Chronic dosing of alkalizing agents was 
first employed by (Joyce et al. 2012) with sodium bicarbonate in an effort elicit an 
ergogenic effect while minimizing GI upset, which often occurs with acute dosing 
protocols. Furthermore, this is also the first study that we know of to investigate the 
potential ergogenic effects of Na-CIT in adolescent athletes. Swimmers are often young 
when they reach elite level competition. The 2012 Olympics reported that among the 
swimming medalists, twenty-five were under 21yrs. and eight were under 18yrs. 
Therefore, investigating ergogenic aids in young competitive swimmers is relevant, and 
until now, lacking in the literature. 
 The 200m performance times were not improved with Na-CIT ingestion in either 
ACU versus PLC-A or CHR versus PLC-C. Na-CIT is postulated to work predominantly as 
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an alkalizing agent; however, more study is needed on its intracellular effects. Lactate 
facilitation out of working muscle is increased under alkalotic conditions during and 
post-exercise compared to placebo (Robergs et al. 2005, Sostaric et al. 2006). However, 
post-trial lactate concentrations were also not statistically different between trials. The 
literature is predominantly in agreement: lactate concentrations are significantly higher 
post-exercise with Na-CIT ingestion compared with control or placebo (Linossier et al. 
1997, McNaughton 1990, McNaughton & Cedaro 1992, Oopik et al. 2003, Shave et al. 
2001), even when performance outcomes are not improved with supplementation 
(Ibanez et al. 1995, Kowalchuk et al. 1989, Oopik et al. 2003). Therefore, a higher lactate 
concentration post-trial, with Na-CIT ingestion, was expected.  
Interestingly, when factoring the age of the sample population of this study, a 
possible explanation emerges. Children and adolescents have been found to have age-
related divergences in muscle metabolism compared to adults (Beneke et al. 2005). It is 
well established that energy provision from anaerobic glycolysis is lower in children than 
adults during high-intensity exercise (Boisseau & Delamarche 2000, Ratel et al. 2002). 
The difference may be explained by several factors: i) reduced activity of PFK (Boisseau 
& Delamarche 2000, Eriksson et al. 1973, Falk & Dotan 2006, Fournier et al. 1982), ii) 
lower activity of lactate dehydrogenase (Boisseau & Delamarche 2000, Eriksson et al. 
1973, Falk & Dotan 2006, Fournier et al. 1982), iii) limited ability to recruit and use 
higher-hierarchy motor units possibly due to neuromuscular immaturity (Dotan et al. 
2012, Falk & Dotan 2006), and iv) a greater reliance on aerobic oxidative enzymes for 
energy provision (Beneke et al. 2005, Boisseau & Delamarche 2000, Falk & Dotan 2006). 
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Furthermore, this difference may be the reason for the smaller intramuscular pH change 
and lower lactate concentration found in children and adolescents after maximal 
exercise compared to adults (Beneke et al. 2005, Dotan et al. 2003, Falk & Dotan 2006, 
Eriksson et al. 1973, Ratel et al. 2002). While training can affect these mechanisms and 
shift the response to that of an average adult (Fournier et al. 1982) the population of 
this study were regional and national level qualifiers and therefore do not train at an 
elite capacity. Taken together, these findings provide a possible explanation for the lack 
of a significant improvement in swim time and change in lactate concentration post-
trial. 
 The magnitude of the response to Na-CIT was not consistent across all 
participants. Similar to the potential difference in physical maturity level found in 
adolescents 13 – 17 years of age, a difference in performance was found in response to 
plasma alkalization. Given the age-related divergences in muscle metabolism, we 
investigated the potential to find participants that respond to Na-CIT at a greater 
magnitude than others. Therefore, the data were analyzed for responders and non-
responders. Responders were chosen if they had greater than 0.4% improvement, which 
corresponds to a significant competitive improvement (Pyne et al. 2004, Trewin et al. 
2004), in ACU versus PLC-A. From the sample population, there were five responders 
and five non-responders. Interestingly, responders were characterized with a higher 
mean age, body mass and BMI compared to non-responders (Table 2); however, this did 
not reach statistical significance.  
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The responders had a significant 1.03% mean performance improvement in the 
ACU trial, but not in the CHR trial. Similarly, post-trial lactate concentrations were higher 
in the ACU trial, but not in the CHR trial. When compared to non-responders, 
responders had higher post-trial lactate concentrations in both the ACU and CHR trials. 
In fact, Na-CIT did not induce any ergogenic or ergolytic effect in non-responders and 
they did not attain typical blood lactate concentrations after the 200m time trials, as 
was observed for the responders. Therefore, those who developed higher post-trial 
lactate levels benefited from the acute supplementation. These findings are supported 
by the established age-related divergences in muscle metabolism and provide further 
evidence on the effectiveness of Na-CIT supplementation in the older adolescent 
swimmers who make up the group of responders.   
Paramount for coaches and athletes is the magnitude of worthwhile 
performance enhancement that can be gained from an ergogenic aid. A key limitation to 
sport specific studies, especially when studying elite athletes, is finding a worthwhile 
improvement in performance while coinciding with a statistically significant 
improvement. Statistical significance at p<0.05 can sometimes be too stringent with 
respect to finding a meaningful improvement in performance. The argument can be 
made that any improvement in elite sport would be welcomed by coaches and athletes. 
Indeed, the smallest worthwhile change for competition performance is 0.4% in Olympic 
level swimmers when comparing finalists to medalists (Pyne et al. 2004, Trewin et al. 
2004). This corresponds to ~0.25s in 100m events and ~0.5s in 200m events (Anderson 
et al. 2008). Although, the performance improvement in the ACU trial was statistically 
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significant; an agreement should be made that when testing competitive athletes, 
minimum competitive significance should be established, independent of statistical 
significance. 
The effect on both swimming performance and plasma alkalization was 
dependent on the supplementation protocol. The ACU protocol benefited the 
performance of the responders; however, CHR protocol did not yield any significant 
improvement or increase lactate concentration. The CHR protocol was enacted to 
incrementally increase plasma BE over a longer time period to allow similar blood 
alkalization with a smaller dose 120min pre-trial. The rationale behind the novel dosing 
method was to minimize potential for performance inhibiting GI upset. Perhaps the CHR 
dose pre-trial was insufficient to elicit performance enhancement, even with the chronic 
dosing protocol over the previous three days. Another factor may be the period of time 
between the last chronic dose and the pre-trial dose of Na-CIT. Optimally, the pre-trial 
dose would have been the morning after the last chronic dose; however, the swims 
were performed in the late afternoon. Further experimentation with the timing of the 
last chronic dose and the pre-trial dose may be necessary to find an optimal protocol, 
should one exist. On the other hand, BE was significantly increased at the basal time 
point comparing CHR versus ACU. Whether this is due to physiological variations or an 
actual effect of the dosing protocol cannot be proven as no measurements were made 
to track the kinetics of Na-CIT during the CHR dosing period. The increase in BE at the 
basal time point did not coincide with an increase in bicarbonate at the same time point. 
PCO2 was unchanged between and within conditions. Therefore, we can conclude that 
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the change in BE was due to the change in bicarbonate and not due to respiratory 
changes. BE reflects only the non-respiratory component of pH disturbances in 
extracellular fluid; therefore, the lack of a significant increase in bicarbonate is 
unknown. Plasma BE and bicarbonate concentration were in line with the values 
reported in the literature post-ingestion (Kowalchuk et al. 1989, Linossier et al. 1997, 
Street et al. 2005). Both the ACU and CHR trials resulted in significant increases in BE 
and bicarbonate; however, this did not translate to a comparable difference post-trial. 
 
5.2 Conclusion 
 
In this double-blind, placebo controlled, cross-over trial Na-CIT supplementation showed 
a significant ergogenic in the adolescent swimmers. More, specifically, acute 
supplementation of Na-CIT provided sufficient alkalization for performance 
enhancement in 200m time trials in responders who were older and in the later stages 
of physiological maturity. Post-trial lactate concentrations were also higher for this 
group. However, the novel chronic supplementation protocol was not significantly 
advantageous for responders and non-responders. Although it did provide a significantly 
increased BE and bicarbonate concentration post-ingestion, this increase was not as 
significant as what was measured in the ACU supplementation. Adequate timing of the 
CHR dosing before the trial day may have been a factor in the lead up to the basal time 
measurement. Therefore, the null hypotheses of no differences in 200m performance 
time between the ACU and PLC-A, the CHR and PLC-C, and the ACU and CHR trials are 
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accepted. However, when considering possible age related divergences in muscle 
metabolism, amongst responders the null hypothesis of no differences in 200m 
performance time between the ACU and PLC-A trials is rejected.  
  
5.3 Study Limitations and Recommendations 
 
The small sample size was the main limiting factor of this study, which may have 
resulted in the lack of significance. In addition, due to laboratory equipment 
malfunction, not all samples of BE, bicarbonate, and PCO2 were completed. Therefore, 
there was not an equal sample size between groups when the variables were analyzed. 
The literature reports that bicarbonate concentration post-exercise is still significantly 
higher with an equal drop compared to placebo (Robergs et al. 2005). This higher 
bicarbonate concentration post-exercise allows for an improved rate of recovery. 
Perhaps the slight increase in bicarbonate post-exercise balances the recovery kinetics 
in favour of the alkalotic condition. Acidosis affects pH sensitive transport proteins and 
glycolytic mechanisms, which in turn affects cell homeostasis. While these may be 
factors in the improved recovery kinetics, this study was not able to definitively prove 
this hypothesis. 
 The within-athlete design used in the present study poses some unique 
challenges to researchers. In sport, it is often difficult to include a control group in the 
experimental design. Often sample size is not large enough for adequate statistical 
power to test all desired variables (Table 1), as was the case in this study. Confounding 
58 
 
variables are numerous and pose a risk to researchers attempting multi-day trials over a 
long period of time. Factors such as the training cycle of the participants may change, or 
training effects on performance can cause skewed results. Furthermore, psychological 
performance factors or physical health can detrimentally affect performance outcomes. 
The analysis comparing responders to non-responders was an unpredicted 
observation during the inception of the study. As a result, characterization of each group 
of participants can only be made through age and body mass. Responders were 
characterized as being older and having a higher body mass than non-responders. This 
suggests that they were potentially in the later stages of physical maturity; however, 
sexual maturation was not measured. Furthermore, lean body mass was not measured, 
which may have been a more useful indicator comparing responders to non-responders 
than body mass alone. 
 
5.4 Future Research 
 
In future studies, where Na-CIT supplementation is used among participants with wide 
ranges of body mass, a new dosing method may be employed to minimize potential for 
fluid retention. This has been considered a potential hindrance to performance when 
ingesting an alkalizer in a dissolved solution (Oopik et al. 2004). Future protocols should 
adjust the volume of fluid, at a standard dose, to drink per body mass instead of a 
standard fluid volume of 500mL for an adjusting dose of Na-CIT per body mass. This way 
each participant would consume a volume of fluid according to their body mass in order 
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to control for the potential of changes in body mass and fluid retention of participants 
with different body masses. 
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Appendix 1 
Ratings of Perceived Exertion 
 
6 
7 VERY, VERY LIGHT 
8 
9 VERY LIGHT 
10 
11 FAIRLY LIGHT 
12 
13 SOMEWHAT HARD 
14 
15 HARD 
16 
17 VERY HARD 
18 
19 VERY, VERY HARD 
20 
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Appendix 2 
Brock Research Ethics Board Letter of Approval 
 
 
72 
 
Appendix 3 
Health Canada Letter of Approval 
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Appendix 4 
Letter of Invitation 
Letter of invitation to participate in a research study: 
 
Effects of acute versus chronic dosing of sodium citrate on 
200m swimming performance 
 
Dear swimmer, 
I, Colin Russell, am a Masters student with the Faculty of Applied Health Sciences at 
Brock University, tel: (905) 301-2848, email: cr11af@brocku.ca. I am performing a 
study on the effects of sodium citrate on swimmers in 200m events. The supervisor 
of the study is Dr. Nota Klentrou of the Faculty of Applied Health Sciences, email: 
nklentrou@brocku.ca. Permission to conduct the study has been granted from the 
Brock University Research Ethics Board. 
 
Male swimmers will randomly perform 4 trials conducted on 4 occasions during 
racing season (October-April) separated by a length of time equal to or greater than 
one week. In this study, swimmers will be asked to also complete a specific 200m 
event of their preferred stroke four times as part of each trial. One trial will be with 
a compound known as sodium citrate at a high dose, another with sodium citrate at 
a low dose (chronic dose) but taken over 4 days, three times a day, and the other 
two with a placebo either at high, single dose or at low dose taken over 4 days. On 
the race day of each trial the sodium citrate will be taken 100-120 minutes prior to 
your maximal effort race. Randomization of when the compound or placebo is to be 
ingested will be in effect.   
 
The swims for the study will be completed in time trial format on a date to be 
announced. Swimmers will be asked to refrain from activities that require large 
amounts of energy and could possibly affect performance during the study, and you 
should not drink alcohol within 12 hours of the testing, or consume caffeine within 6 
hours of the testing. The time commitment for each trial will be 2 hours.  
  
We will be asking for information about your date of birth, height, weight, and 
physical wellbeing as well as best times. A Medical History Questionnaire will be 
used to screen for general health and medication use that may be a safety concern to 
the participant.  Other information will come from blood work. Blood will be drawn 
via finger prick. Blood work will be done with an automated lactate analyzer 
(Arkray Lactate Pro LT-1710 and I-Stat-1) to determine whole blood lactate (Pyne 
et al., 2000) and other blood variables. With a finger prick there is a small risk of 
bruising and infection. This blood work will be done pre-ingestion, pre-race and 
post-race. Lactic acid levels in the blood will be recorded pre-ingestion, pre-race, 
and post-race. 
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We hope that the results will contribute to our understanding of sodium citrate and 
its potential as an ergogenic aid. Sodium citrate is a legal substance that is not 
banned by the Canadian Centre for Ethics in Sport or the World Anti Doping Agency 
and could potentially affect the results of performances in swimmers and by 
extension other athletes. Further, the knowledge gained from the study may assist 
the coaches and athletes in future competitions. 
 
There may be certain risks associated with participation in the study. The risks and 
measures to be taken by the researchers to minimize the risks are: 
 
1. Finger bruising and infection will be prevented by adhering to proper technique 
(disinfecting and cleansing of the fingers before and after the finger prick) for finger 
pricking. Participants will be provided with a band-aid for their fingers. Bruising will 
also be minimized by alternating finger to prick. 
 
2. The possible side effects of taking sodium citrate include: stomach ache or 
cramping, nausea, vomiting, and diarrhea. These risks will be minimized by 
providing participants with sodium citrate in solution with 500mL of flavoured 
water to aid in taking a dose that has been previously reported in several research 
studies in this age range.  
 
Prior to conducting the study, I will obtain written, informed consent from the 
swimmers. There is no obligation to participate in the study and the swimmer may 
withdraw from study at any time without affecting the coaching that the swimmer 
may receive. All information collected during the study will not identify the 
swimmer and by name. 
 
Thank you for your interest in hearing about the study. If you wish to participate 
please contact me at the number or email listed below. 
 
Colin Russell, cr11af@brocku.ca, (905) 301-2848 
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Appendix 5 
Parent / Guardian Informed Consent 
RESEARCH STUDY INFORMATION AND  
PARENTAL OR GURADIAN CONSENT 
 
Effects of acute versus chronic dosing of sodium citrate on 
200m swimming performance 
  
 
You child is being asked to take part in a research study. This research is intended to 
test the effectiveness of sodium citrate as a legal ergogenic supplement for maximal 
exercise performance. Before agreeing to allow participation in this study, it is 
important that you read and understand the following explanation of the proposed 
study procedures. The following information describes the purpose, procedures, 
benefits, discomforts, risks and precautions associated with this study. It also 
describes your right to refuse to allow participation or withdrawal from the study at 
any time. In order to decide whether you wish to allow your child to participate in 
this research study, you should understand enough about its risks and benefits to be 
able to make an informed decision. This is known as the informed assent process. 
Please ask the study doctor (Dr. Nota Klentrou) or study staff to explain any words 
you don’t understand before signing this assent form. Make sure all your questions 
have been answered to your satisfaction before signing this document. 
 
Purpose 
 
The purpose of this study is to determine the potential performance enhancing 
effects of sodium citrate on male swimmers 13-17 years of age. Sodium Citrate has 
been studied in other sports over a broad array of doses, times, and distances with 
inconclusive results. This study seeks to find any potential effects for a certain 
distance in a specific sport. 
 
In the course of this study we will monitor the response of various physiological 
variables involved in keeping your child’s blood acid levels balanced, and also their 
blood lactate levels.  
 
The results of the study will help us understand how the sodium citrate may 
work to improve athletic performance. 
 
Procedures 
 
Participants will randomly perform 4 trials conducted on 4 occasions during racing 
season (October-April) separated by a length of time equal to or greater than one 
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(1) week.  More specifically, the swimmers will be asked to also complete a specific 
200m event of their preferred stroke four times as part of each trial. One trial will be 
with a compound known as sodium citrate at a high dose of 0.5g/kg in solution with 
flavoured water, another with sodium citrate at a low dose (chronic dose) of 0.1 
g/kg but taken over 3 days, three times a day and on the fourth day (trial day) one 
dose at 0.3g/kg also in solution with flavoured water. The other trials will be with a 
placebo, flavoured water only at the same frequency as the acute or chronic protocol 
depending on your trial group.  On the race day of each trial the sodium citrate will 
be taken 100-120 minutes prior to your maximal effort race. Warm-up and warm-
down procedures will be based solely on each swimmers typical regimen. 
Randomization of when participants take sodium citrate or placebo will occur.  
  
Physiological data will be collected from you pre-ingestion, pre-race, and post-race. 
A venous blood sample will be collected after a finger prick and analyzed 
immediately by an automated lactate analyzer (Arkray Lactate Pro LT-1710 and I-
Stat-1) to determine whole blood lactate and other blood variables (see attached 
list).  
 
Your child will be asked to refrain from abnormal, energy consuming lifestyle 
choices (staying up late, working out more than normal for a given week, ect.) 
between the four swims. Participants must refrain from using caffeine and alcohol 
for 6 and 12 hours respectively before testing. Your child should also maintain a 
similar diet and supplement use during the study. The time commitment for each trial 
will be 2 hours.  
 
Risks 
 
There may be certain risks associated with participation in the study. Bruising and 
infection of the fingers may occur as a result of the finger prick during the lactate 
test and blood test. Finger bruising and infection will be prevented by adhering to 
proper technique (disinfecting and cleansing of the fingers before and after the 
finger prick) for finger pricking. Furthermore, we will alternate fingers when 
performing a finger prick. 
 
Stomach ache or cramping, nausea, vomiting and/or diarrhea due to sodium citrate 
ingestion may also occur. Sodium citrate risks will be minimized by providing 
participants with sodium citrate in solution with 500mL of flavoured water to aid in 
taking a dose that has been previously reported in several research studies in this 
age range. After your child stop taking the dose of sodium citrate it should no longer 
by in their system after 2.5 days under normal circumstances. Dr. Matt J. Greenway 
will be available in case any problems occur during the study period. All serious 
adverse events will be immediately reported to Health Canada and any reported 
minor discomforts will be recorded.  
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Sodium citrate is a legal substance and is not banned by the Canadian Centre for 
Ethics in Sport or the World Anti Doping Agency. 
 
Benefits 
 
You will receive no benefit from your participation in this study. Information 
learned from this study may benefit athletes in the future.   
 
Confidentiality 
 
All information obtained during the study will be held in a password protected 
server in strict confidence in a locked office at Brock University for a period of 5 
years, after which it will be destroyed. Research records will be stored in a 
confidential manner so as to protect the confidentiality of your information. You will 
be identified with a study number only. No names or identifying information will be 
used in any publication or presentations. Health Canada may have access to the 
records at anytime. 
 
Participation 
 
Your child’s participation in this study is voluntary.  You can choose not to allow 
them to participate or you may withdraw them at any time without consequences.  
 
Reimbursements / Compensation 
 
There is no compensation for participation in this study, 
 
Questions  
 
If your child suffers any side effects or other injuries during the study, or if you have 
any general questions about the study, please see Dr. Matt J. Greenway on site for 
this study.  
  
If you have any questions about your rights as a parent or guardian of a research 
participant, please contact the Brock University Research Ethics Officer (905-688-
5550 ext 3035; reb@brocku.ca). This study has been reviewed and received ethics 
clearance through Brock University’s Research Ethics Board (file # 12-009) Please 
keep a copy of this consent form for your records.  
Consent  
 
I have had the opportunity to discuss this study and my questions have been 
answered to my satisfaction. Signing this does not release the investigators from 
negligence or liability.  I consent to take part in the study with the understanding I 
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may withdraw at any time. I have received a signed copy of this consent form. I 
voluntarily consent to participate in this study.  
 
 
 
_________________________              _________________________________               ____________ 
Parent or Guardian’s Name       Parent or Guradian’s Signature                      Date  
(Please Print) 
 
 
 
I confirm that I have explained the nature and purpose of the study to the subject 
named above. I have answered all questions.   
 
 
 
_________________________  _________________________________              _______________ 
Name of Person            Signature      Date 
Obtaining Consent 
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Appendix 6 
Participant Informed Assent 
RESEARCH STUDY INFORMATION AND ASSENT 
 
Effects of acute versus chronic dosing of sodium citrate on 
200m swimming performance 
  
 
You are being asked to take part in a research study. This research is intended to 
test the effectiveness of sodium citrate as a legal ergogenic supplement for maximal 
exercise performance. Before agreeing to participate in this study, it is important 
that you read and understand the following explanation of the proposed study 
procedures. The following information describes the purpose, procedures, benefits, 
discomforts, risks and precautions associated with this study. It also describes your 
right to refuse to participate or withdraw from the study at any time. In order to 
decide whether you wish to participate in this research study, you should 
understand enough about its risks and benefits to be able to make an informed 
decision. This is known as the informed consent process. Please ask the study doctor 
(Dr. Nota Klentrou) or study staff to explain any words you don’t understand before 
signing this consent form. Make sure all your questions have been answered to your 
satisfaction before signing this document. 
 
Purpose 
 
The purpose of this study is to determine the potential performance enhancing 
effects of sodium citrate on male swimmers 13-17 years of age. Sodium Citrate has 
been studied in other sports over a broad array of doses, times, and distances with 
inconclusive results. This study seeks to find any potential effects for a certain 
distance in a specific sport. 
 
In the course of this study we will monitor the response of various physiological 
variables involved in keeping your blood acid levels balanced, and also your blood 
lactate levels.  
 
The results of the study will help us understand how the sodium citrate may 
work to improve athletic performance. 
 
Procedures 
 
Participants will randomly perform 4 trials conducted on 4 occasions during racing 
season (October-April) separated by a length of time equal to or greater than one 
(1) week.  More specifically, the swimmers will be asked to also complete a specific 
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200m event of their preferred stroke four times as part of each trial. One trial will be 
with a compound known as sodium citrate at a high dose of 0.5g/kg in solution with 
flavoured water, another with sodium citrate at a low dose (chronic dose) of 0.1 
g/kg but taken over 3 days, three times a day and on the fourth day (trial day) one 
dose at 0.3g/kg also in solution with flavoured water. The other trials will be with a 
placebo, flavoured water only at the same frequency as the acute or chronic protocol 
depending on your trial group. On the race day of each trial the sodium citrate will 
be taken 100-120 minutes prior to your maximal effort race. Warm-up and warm-
down procedures will be based solely on each swimmers typical regimen. 
Randomization of when participants take sodium citrate or placebo will occur.  
  
Physiological data will be collected from you pre-ingestion, pre-race, and post-race. 
A venous blood sample will be collected after a finger prick and analyzed 
immediately by an automated lactate analyzer (Arkray Lactate Pro LT-1710 and I-
Stat-1) to determine whole blood lactate and other blood variables (see attached 
list).  
 
You will be asked to refrain from abnormal, energy consuming lifestyle choices 
(staying up late, working out more than normal for a given week, ect.) between the 
two swims. Participants must refrain from using caffeine and alcohol for 6 and 12 
hours respectively before testing. You should also maintain a similar diet and 
supplement use during the study. The time commitment for each trial will be 2 hours.  
 
Risks 
 
There may be certain risks associated with participation in the study. Bruising and 
infection of the fingers may occur as a result of the finger prick during the lactate 
test and blood test. Finger bruising and infection will be prevented by adhering to 
proper technique (disinfecting and cleansing of the fingers before and after the 
finger prick) for finger pricking. Furthermore, we will alternate fingers when 
performing a finger prick. 
 
Stomach ache or cramping, nausea, vomiting and/or diarrhea due to sodium citrate 
ingestion may also occur. Sodium citrate risks will be minimized by providing 
participants with sodium citrate in solution of 500mL of flavoured water to aid in 
taking a dose that has been previously reported in several research studies in this 
age range. After you stop taking the dose of sodium citrate it should no longer by in 
your system after 2.5 days under normal circumstances. Dr. Matt J. Greenway will be 
available in case any problems occur during the study period. All serious adverse 
events will be immediately reported to Health Canada and any reported minor 
discomforts will be recorded. 
 
Sodium citrate is a legal substance and is not banned by the Canadian Centre for 
Ethics in Sport or the World Anti Doping Agency. 
 
Benefits 
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You will receive no benefit from your participation in this study. Information 
learned from this study may benefit athletes in the future.   
 
Confidentiality 
 
All information obtained during the study will be held in a password protected 
server in strict confidence in a locked office at Brock University for a period of 25 
years, after which it will be destroyed. Research records will be stored in a 
confidential manner so as to protect the confidentiality of your information. You will 
be identified with a study number only. No names or identifying information will be 
used in any publication or presentations. Health Canada may have access to the 
study records at anytime. 
 
Participation 
 
Your participation in this study is voluntary. You can choose not to participate or 
you may withdraw at any time without consequences.  
 
Reimbursements / Compensation 
 
There is no compensation for participation in this study, 
 
Questions  
 
If you suffer any side effects or other injuries during the study, or if you have any 
general questions about the study, please see Dr. Matt J. Greenway on site for the 
study. 
  
If you have any questions about your rights as a research participant, please contact 
the Brock University Research Ethics Officer (905-688-5550 ext 3035; 
reb@brocku.ca). This study has been reviewed and received ethics clearance 
through Brock University’s Research Ethics Board (file # 12-009). Please keep a 
copy of this consent form for your records.  
Consent  
 
 I have had the opportunity to discuss this study and my questions have been 
answered to my satisfaction. Signing this does not release the investigators from 
negligence or liability.   I consent to take part in the study with the understanding I 
may withdraw at any time. I have received a signed copy of this consent form. I 
voluntarily consent to participate in this study.  
 
 
 
82 
 
_________________________              _________________________________               ____________ 
Study Participant’s Name       Study Participant’s Signature                       Date  
(Please Print) 
 
I confirm that I have explained the nature and purpose of the study to the subject 
named above. I have answered all questions.   
 
 
 
 
 
_________________________  _________________________________             _______________ 
Name of Person            Signature      Date 
Obtaining Consent 
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Appendix 7 
Raw Data 
Participant Trial 
Order 
Age 
(yrs) 
 Doses (g)    Lactate 
(mmol/L) 
   BM 
(kg) 
0.1 0.3 0.5 Stroke Time 
(s) 
RPE Lac 
1 
Lac 
2 
Lac 
3 
1 1 15 69.5 7.0 20.9 34.8 Backstroke 145.5 17 0.94 1.6 10.7 
 2       145.7 17 1 2.1 10 
 3       145.7 17 1 0.9 12.2 
 4       145.9 18 1.14 0.71 8.6 
2 1 16 74.1 7.4 22.2 37.1 I.M. 154.5 17 1.4 0.9 7.4 
  2             154.6 12 1.1 4.3 6.4 
  4             153.8 16 1.8 1.8 7.3 
  3             158.6 18 0.8 1.6 4.9 
3 2 16 83.6 8.4 25.1 41.8 Freestyle 125.66 18 2.2 1.9 13.6 
 1       126.5 18 1.4 1.6 10.3 
 3       126.6 16 1 1.8 12.3 
 4       124.9 19 1.1 1.1 13.6 
4 1 16 64.2 6.4 19.3 32.1 Freestyle 130.5 17 0.62 1.1 6.4 
 3       127.9 17 0.7 0.7 8.2 
 2       128 16 0.7 0.8 8.4 
 4       128.4 18 1.83 0.7 8.6 
5 2 17 77.3 7.7 23.2 38.7 Freestyle 129.5 18 2.3 1.1 15.7 
 3       129.6 15 0.9 1.1 9.8 
 1       131.2 16 1.16 0.9 9.9 
 4       130.4 18 1 0.8 10.8 
6 1 14 56.5 5.7 17.0 28.3 Freestyle 135.5 18 1.18 1.2 5.3 
 2       136.2 16 0.9 1.9 4.3 
 4       133.3 16 0.7 0.8 5.7 
 3       131 17 1.4 1.7 5.9 
7 2 14 49.1 4.9 14.7 24.6 Breastroke 168.5 17 1.1 1.2 5.6 
 3       170.4 16 0.9 0.8 5.7 
 1       161.6 13 1.4 1.8 8.8 
 4       164.6 13 1.4 1.3 7.9 
8 2 15 62.5 6.3 18.8 31.3 Freestyle 126.5 15 1.2 1.4 15 
 4       126.5 17 1 1.6 10.1 
 1       127.8 14 1.4 1.2 8.6 
 3       127.7 16 0.84 1.1 9.9 
9 2 13 47.7 4.8 14.3 23.9 Freestyle 159.5 17 1.2 1.2 7.2 
 1       155.8 15 1.2 1.3 7 
 3       155.1 16 1.8 1.1 6.9 
 4       156.5 17 1.7 0.9 15.1 
10 1 13 50.6 5.1 15.3 25.5 Breastroke 166.0 19 1.2 0.9 12.1 
 4       170.7 19 0.9 1.3 11.7 
 3       164 18 1.1 1.9 13.8 
 2       165.3 15 1.7 1 12.2 
             
 1=PLC-
A 
3=CHR           
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 2=ACU 4=PLC-
C 
          
 
Trial BE1 
(mmol/L) 
BE2 BE3 BICARB1 
(mmol/L) 
BICARB2 BICARB3 PCO2_1 
(mmHg) 
PCO2_2 PCO2_3 
1 1 -2 -13 24.6 24 14.3 39.2 37.6 33 
1 -2 -2  22.5 22.8  36.7 36.2  
1 2 -1  26.6 25  40 39.8  
1 0 -1  26.3 22.5  43.2 34.1  
1 0 0  24.6 23  39.1 35.2  
1 1   25   38.9   
1 2   26.5   42   
2 1 8 -3 25.2 31.3 22.5 39.3 40.4 40.6 
2 -1 3 -11 23.6 27 16 35.8 39.3 34.4 
2 -2 8 -3 23.1 31.6 21.9 36.8 41.9 37.5 
2 -1 9 -12 23.4 32.1 14.7 35.5 41.8 29.8 
2 0 6  24.5 28.7  38.5 34.9  
3 1 6 -7 24.8 29.3 19 36.2 39.4 34.4 
3 1 0 -10 25.6 24.3 16.3 37.7 36.8 34.3 
3 2 7 -9 27 29.6 17.1 42.5 35 35.3 
3 0 5 -15 24.3 29.1 12.8 37.8 41.8 31.3 
3 2 6 -3 26.1 29 22.4 40.2 37.4 39.1 
3 1 6  24.4 29.9  34.4 40.2  
4 1 1 -12 25.4 24.9 15.4 38.2 36.9 34.3 
4 1 -2 -19 25.6 22.8 10.3 38.5 35.6 29.8 
4 1 -2 -17 24.6 23 11.6 35.6 37.1 30.8 
4 2 -1 -7 26 23.6 18.6 39.3 36.4 35.4 
4 1 1 -10 25.6 25.1 16.6 41.8 38.9 36.7 
4 0 1 -11 24.7 25.2 15.9 38.9 38 35.9 
4 1  -14 25.2  14.2 39.7  35.5 
4   -5   21   38.1 
 
